Ioanna Giopanou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9285250/publications.pdf

Version: 2024-02-01

687363 642732 24 700 13 23 citations h-index g-index papers 29 29 29 1400 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells, 2019, 8, 815.	4.1	109
2	Mast cells mediate malignant pleural effusion formation. Journal of Clinical Investigation, 2015, 125, 2317-2334.	8.2	89
3	Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nature Communications, 2019, 10, 1405.	12.8	68
4	Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. ELife, 2019, 8, .	6.0	46
5	Ontogenetic differentiation of swimming performance in Gilthead seabream (Sparus aurata, Linnaeus) Tj ETQq1 1	1 0.784314 1.5	1 rggBT /Ov <mark>er</mark>
6	Deficiency in apolipoprotein $\hat{a} \in fE$ has a protective effect on diet $\hat{a} \in fE$ nduced nonalcoholic fatty liver disease in mice. FEBS Journal, 2011, 278, 3119-3129.	4.7	39
7	llºB Kinase l̂± Is Required for Development and Progression of <i>KRAS</i> Cancer Research, 2018, 78, 2939-2951.	0.9	36
8	Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion. PLoS ONE, 2013, 8, e71207.	2.5	33
9	<i> <scp>NRAS</scp> </i> destines tumor cells to the lungs. EMBO Molecular Medicine, 2017, 9, 672-686.	6.9	31
10	Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis. Oncolmmunology, 2017, 6, e1256528.	4.6	29
11	Myeloid-derived interleukin- $1\hat{l}^2$ drives oncogenic KRAS-NF- $\hat{l}^2\hat{l}$ addiction in malignant pleural effusion. Nature Communications, 2018, 9, 672.	12.8	28
12	Comprehensive Evaluation of Nuclear Factor-Îণী' Expression Patterns in Non-Small Cell Lung Cancer. PLoS ONE, 2015, 10, e0132527.	2.5	25
13	Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study. BioMed Research International, 2014, 2014, 1-8.	1.9	16
14	Interleukin- $1\hat{l}^2$ provided by KIT-competent mast cells is required for <i>KRAS</i> mutant lung adenocarcinoma. Oncolmmunology, 2019, 8, e1593802.	4.6	15
15	Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter. Carcinogenesis, 2019, 40, 1352-1362.	2.8	14
16	Osteopontin drives KRAS-mutant lung adenocarcinoma. Carcinogenesis, 2020, 41, 1134-1144.	2.8	14
17	Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors. Cancer Medicine, 2019, 8, 1486-1499.	2.8	13
18	RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Critical Reviews in Oncology/Hematology, 2020, 146, 102859.	4.4	12

#	Article	IF	CITATIONS
19	KRAS signaling in malignant pleural mesothelioma. EMBO Molecular Medicine, 2022, 14, e13631.	6.9	12
20	The expression of p-mTOR and COUP-TFII correlates with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 311.e27-311.e35.	1.6	11
21	Synergistic Combination of Calcium and Citrate in Mesoporous Nanoparticles Targets Pleural Tumors. CheM, 2021, 7, 480-494.	11.7	11
22	Lung carcinogenesis and fibrosis taken together. Current Opinion in Pulmonary Medicine, 2017, 23, 290-297.	2.6	5
23	A link between <i>Rel</i> B expression and tumor progression in laryngeal cancer. Oncotarget, 2017, 8, 114019-114030.	1.8	4
24	An airway epithelial origin for tobacco carcinogen-induced lung adenocarcinoma. , 2015, , .		1